证券代码：600846 股票名称：同济科技 公告编号：2025-025 | 项目 | 1-6 | 月新签合同数量 | 月新签合同金额 1-6 | | --- | --- | --- | --- | | | （1000 | 万元以上） | （万元） | | 房屋建设 | | 5 | 214,088.61 | | 建筑装饰 | | 1 | 2,585.28 | | 专业工程 | | 4 | 25,725.64 | | 合计 | | 10 | 242,399.53 | 截至本公告披露日，公司不存在已签订但尚未执行的重大项目的情况。 以上数据为阶段性数据，仅供投资者参考，最终数据以定期报告披露数据为 准。 特此公告。 上海同济科技实业股份有限公司 2025 年上半年新签合同情况公告 | 特别提示 | | --- | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 | | 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 2025 年 1 月至 6 月，上海同济科技实业股份有限公司（以下简称"公司"） 新签施工合同额约人民币 24.54 亿元，较上年同期减少 19.28%；其中 ...

证券代码：600846 证券简称：同济科技 公告编号：2025-026 上海同济科技实业股份有限公司 第十届董事会 2025 年第四次临时会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二〇二五年七月二十六日 1 附件： 官远发先生简历 上海同济科技实业股份有限公司（以下简称"公司"）第十届董事会 2025 年第四次临时会议于 2025 年 7 月 25 日以现场结合通讯方式召开，会议资料于 2025 年 7 月 22 日以电子方式发出。本次会议应参加表决的董事 9 名，实际参加 表决董事 9 名，共同推举董事余翔先生主持会议，公司监事及部分高级管理人员 列席会议。本次会议的通知、召开及表决程序符合相关法律、法规、规则及《公 司章程》的有关规定。 会议审议通过了《关于选举公司董事长暨变更法定代表人、战略委员会主任 委员的议案》，同意选举官远发先生（简历见附件）为公司董事长，任期与本届 董事会相同。根据《公司章程》《公司战略委员会实施细则》的规定，官远发先 生作为公司董事长，同时担任法定代表人、战略委员会 ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

Group 1 - Rongzhi Rixin expects a net profit increase of 2,027.62% to 2,179.59% for the first half of 2025, with projected profits between 14 million to 15 million yuan [1] - The significant profit growth is attributed to the acceleration of digital and intelligent transformation across industries, leading to increased revenue from sectors like wind power and petrochemicals [1] - The company has improved operational management efficiency, resulting in enhanced gross margins and overall profitability [1] Group 2 - Jinzhai Food plans to repurchase shares worth between 50 million to 100 million yuan, with a maximum repurchase price of 16 yuan per share [2] - The repurchase will be funded through self-owned funds and a special loan from China Merchants Bank, with a loan commitment of up to 90 million yuan [2] Group 3 - Zhongfu Information's chairman and general manager, Wei Dongxiao, has been detained, and the board has arranged for the deputy general manager to assume his responsibilities during this period [3][4] - The company states that this situation will not significantly impact its daily operations [4] Group 4 - Shenzhen Energy plans to invest approximately 789.703 million yuan in the construction of the Honghaiwan offshore wind power project, with a portion funded through financing [6] - The company will increase its capital in its subsidiary by 153.108 million yuan to support this project [6] Group 5 - *ST Zitian faces potential delisting due to failure to rectify false financial reporting as mandated by the China Securities Regulatory Commission [8] - The company has not disclosed corrected financial reports within the required timeframe, leading to a warning of delisting risk [8] Group 6 - Watson Bio has signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Co., aiming to establish a long-term partnership in the vaccine and bioproducts industry [10] - The collaboration is expected to enhance innovation and business expansion in the vaccine sector [10] Group 7 - Weiming Environmental reported a total power generation of 226,162.29 million kWh in the first half of 2025, representing a year-on-year increase of 7.54% [12] - The company also recorded a total waste input of 689.32 million tons, with a growth of 8.71% compared to the previous year [12]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海同济科技实业股份有限公司(以下简称"公司"或"本公司")董事会于近日 收到董事长余翔先生提交的书面辞职报告。因工作调整，余翔先生申请辞去公司 第十届董事会董事长、法定代表人、战略委员会主任委员职务。辞职后，余翔先 生将继续担任公司董事及董事会专门委员会委员职务。 注：公司第十届董事会任期于 2025 年 6 月 29 日届满，公司于 2025 年 6 月 26 日发布《关于 董事会、监事会延期换届的提示性公告》（公告编号：2025-021），公司第十届董事会延期换 届，董事会各专门委员会、高级管理人员的任期亦相应顺延。 二、离任对公司的影响 根据《公司法》《公司章程》等有关规定，余翔先生的辞职未导致公司董事 会成员低于法定人数，辞职申请自送达董事会时生效。余翔先生作为公司董事、 战略委员会委员、薪酬与考核委员会委员继续履职，不会影响公司正常经营。余 翔先生不存在应当履行而未履行的承诺事项，并将按照公司相关规定做好交接工 作。 证券代码：600846 证券简称：同济科技 公告编 ...

本期债券采取网下面向专业投资者簿记建档的方式发行，发行工作已于 2025 年 7 月 15 日结束，本期债券发行规模为 6 亿元，票面利率为 1.75%，全场 认购倍数为 3.17 倍。 经核查，发行人的董事、监事、高级管理人员、持股比例超过 5%的股东及 其他关联方未参与本期发行债券认购。 特此公告。 根据中国证券监督管理委员会《关于同意上海同济科技实业股份有限公司向 专业投资者公开发行公司债券注册的批复》（证监许可〔2025〕821 号），上海同 济科技实业股份有限公司（以下简称"发行人"）获准面向专业投资者公开发行 不超过人民币 10 亿元（含 10 亿元）公司债券。 根据《上海同济科技实业股份有限公司 2025 年面向专业投资者公开发行公 司债券（第一期）发行公告》，发行人 2025 年面向合格投资者公开发行公司债券 （第一期）（以下简称"本期债券"），债券简称"25 同济 01"，债券代码为 242988.SH。 本期债券发行规模不超过人民币 6 亿元（含 6 亿元），期限为 3 年期，发行价格 为 100 元/张。 证券代码：600846 证券简称：同济科技 公告编号：2025-023 上海同济科 ...

上海同济科技实业股份有限公司 简式权益变动报告书 上市公司名称：上海同济科技实业股份有限公司 股票上市地点：上海证券交易所 股票简称：同济科技 股票代码：600846 信息披露义务人：韩朝东 住所：北京市海淀区****** 通讯地址：北京市海淀区****** 股权变动性质：增持股份 签署日期：二〇二五年六月 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证券 法》、《上市公司收购管理办法》及《公开发行证券的公司信息披露内容与格式准 则第 15 号—权益变动报告书》及相关的法律、法规编写本报告。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 收购管理办法》及《公开发行证券的公司信息披露内容与格式准则第 15 号—权 益变动报告书》的规定，本报告书已全面披露了信息披露义务人在上海同济科技 实业股份有限公司拥有权益的股份变动情况。 | | | 第一节 释义 特别说明：本报告书中所列数据可能因四舍五入原因而与根据相关单项数据直接相加之 和在尾数上略有差异。 3 四、截至本报告书签署日，除本报告书披露 ...

证券代码：600846 股票名称：同济科技 公告编号：2025-022 上海同济科技实业股份有限公司 关于股东权益变动的提示性公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动不会使公司控股股东及实际控制人发生变化。 2025 年 6 月 27 日, 上海同济科技实业股份有限公司（以下简称"同济科技" 或"公司"）收到公司股东韩朝东出具的《简式权益变动报告书》。2025 年 4 月 1 日至 2025 年 6 月 27 日，股东韩朝东通过集中竞价交易、大宗交易方式增加 持有公司股份 24,002,116 股，累计持有公司股份 31,238,117 股，占公司总股本的 比例达到 5.00%。具体情况如下： | 信息披露 | 交易方式 | 交易时间 | 股份 | 成交均价 | 买入数量 | | --- | --- | --- | --- | --- | --- | | 义务人 | | （按月统计） | 种类 | （元/股） | （股） | | 韩朝东 | 集中竞 价交易 | 2025年5月 ...

Core Viewpoint - Tongji Technology's 2024 annual shareholder meeting approved all 11 proposals, highlighting the company's focus on leveraging regional resources and academic advantages for steady operations and continuous innovation [2] Financial Performance - In 2024, Tongji Technology achieved an operating income of 4.173 billion yuan and a net profit attributable to shareholders of 406 million yuan, representing a year-on-year growth of 6.51% [2] - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling 1.58 billion yuan, maintaining a cash dividend payout ratio exceeding 30% for 11 consecutive years [2] Business Development - The company secured significant projects, including the expansion of Macau International Airport, and achieved a record new contract amount of 4.059 billion yuan in construction business [2] - Tongji Technology processed 11.7 million tons of wastewater in its environmental protection business and undertook Shanghai's largest urban renewal project [2] - The acquisition of 55% of Shanghai Tongji Testing Technology Co., Ltd. and an additional investment of 120 million yuan aim to strengthen the green environmental operations segment [2] Strategic Focus - The company established a Digital Information Technology Department to accelerate digital business expansion, focusing on digital construction and smart construction [3] - Plans for 2025 include enhancing the full-process professional service industry chain covering project planning, financing, design, construction, management consulting, and operation maintenance [3] - The company aims to deepen regional market engagement and accelerate overseas market expansion through a "fund + base + research institute + industry alliance" development model [3] Management Confidence - The first stock buyback of 30.97 million yuan in 31 years reflects management's confidence in the company's value [3][4] - Future strategies will enhance strategic leadership, scientific decision-making, and risk prevention capabilities, aiming for quality upgrades across business segments [4]

证券代码：600846 股票名称：同济科技 公告编号：2025-021 上海同济科技实业股份有限公司 关于董事会、监事会延期换届的提示性公告 上海同济科技实业股份有限公司董事会 二〇二五年六月二十六日 上海同济科技实业股份有限公司（以下简称"公司"）第十届董事会、监事 会任期将于 2025 年 6 月 29 日届满，根据新修订的《中华人民共和国公司法》《上 市公司章程指引》及《关于新<公司法>配套制度规则实施相关过渡期安排》等 要求，公司拟修订《公司章程》等相关制度并进行换届选举。鉴于公司换届选举 工作仍在筹备中，为确保公司相关工作的连续性和稳定性，公司第十届董事会、 监事会将延期换届，董事会各专门委员会、高级管理人员的任期亦相应顺延。 在换届选举工作完成前，公司第十届董事会和监事会全体成员、董事会各专 门委员会委员及现任高级管理人员将依照相关法律、法规和《公司章程》等有关 规定继续履行相应的义务和职责。公司董事会、监事会延期换届不会影响公司的 正常运营。公司将继续积极推进相关工作，尽快完成董事会、监事会换届选举工 作，并及时履行相应的信息披露义务。 特此公告。 | 特别提示 | | --- | | 本公司董 ...